Blue skies for Codiak

EcoR1 opted to join Codiak BioSciences Inc.’s series C round based on the track record of the biotech’s team and the broad utility of its exosome therapeutics platform. The deal aims to get the company its first clinical data in cancer.

On Nov. 29, Codiak raised $76.5 million in an untranched series C round. In addition to EcoR1, other new investors included Casdin Capital, Qatar Investment Authority, Sirona Capital and Tavistock Group’s Boxer Capital. Existing investors Alaska Permanent Fund, Alexandria Venture Investments, Arch Venture Partners, Fidelity and Flagship Pioneering also participated. ...